| Literature DB >> 17498290 |
Christine Lyn Le Maitre1, Anthony John Freemont, Judith Alison Hoyland.
Abstract
Current evidence implicates intervertebral disc degeneration as a major cause of low back pain, although its pathogenesis is poorly understood. Numerous characteristic features of disc degeneration mimic those seen during ageing but appear to occur at an accelerated rate. We hypothesised that this is due to accelerated cellular senescence, which causes fundamental changes in the ability of disc cells to maintain the intervertebral disc (IVD) matrix, thus leading to IVD degeneration. Cells isolated from non-degenerate and degenerate human tissue were assessed for mean telomere length, senescence-associated beta-galactosidase (SA-beta-gal), and replicative potential. Expression of P16INK4A (increased in cellular senescence) was also investigated in IVD tissue by means of immunohistochemistry. RNA from tissue and cultured cells was used for real-time polymerase chain reaction analysis for matrix metalloproteinase-13, ADAMTS 5 (a disintegrin and metalloprotease with thrombospondin motifs 5), and P16INK4A. Mean telomere length decreased with age in cells from non-degenerate tissue and also decreased with progressive stages of degeneration. In non-degenerate discs, there was an age-related increase in cellular expression of P16INK4A. Cells from degenerate discs (even from young patients) exhibited increased expression of P16INK4A, increased SA-beta-gal staining, and a decrease in replicative potential. Importantly, there was a positive correlation between P16INK4A and matrix-degrading enzyme gene expression. Our findings indicate that disc cell senescence occurs in vivo and is accelerated in IVD degeneration. Furthermore, the senescent phenotype is associated with increased catabolism, implicating cellular senescence in the pathogenesis of IVD degeneration.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17498290 PMCID: PMC2206356 DOI: 10.1186/ar2198
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Intervertebral disc samples used for telomere length assay, senescence-associated β-galactosidase staining, and p16immunohistochemistry
| Laboratory number | Gender | Age (years) | Cell type | Disc level | Cell source | Histological grade |
| 1 | M | 37 | AF | L4/5 | PM | 1 |
| 2 | M | 37 | AF | L5/S1 | PM | 1 |
| 3a | M | 37 | NP | L4/5 | PM | 1 |
| 4a | M | 37 | NP | L5/S1 | PM | 1 |
| 5 | M | 47 | AF | L2/3 | PM | 1 |
| 6 | M | 47 | AF | L3/4 | PM | 1 |
| 7a | M | 47 | NP | L2/3 | PM | 1 |
| 8 | M | 47 | NP | L3/4 | PM | 1 |
| 9 | M | 47 | NP | L5/S1 | PM | 1 |
| 10 | M | 47 | AF | L4/5 | PM | 2 |
| 11 | M | 47 | NP | L4/5 | PM | 2 |
| 12 | M | 59 | NP | L4/5 | PM | 2 |
| 13 | M | 59 | AF | L4/5 | PM | 2 |
| 14 | M | 62 | AF | L3/4 | PM | 2 |
| 15 | M | 62 | AF | L4/5 | PM | 2 |
| 16a | M | 62 | NP | L3/4 | PM | 2 |
| 17 | M | 62 | NP | L4/5 | PM | 2 |
| 18 | M | 37 | AF | L1/2 | PM | 3 |
| 19 | M | 37 | NP | L1/2 | PM | 3 |
| 20 | M | 74 | AF | L3/4 | PM | 3 |
| 21 | M | 37 | AF | L2/3 | PM | 4 |
| 22 | M | 37 | AF | L3/4 | PM | 4 |
| 23 | M | 37 | NP | L2/3 | PM | 4 |
| 24 | M | 37 | NP | L3/4 | PM | 4 |
| 25a | F | 49 | NP | L4/5 | Surgical | 4 |
| 26 | M | 44 | NP | L4/5 | Surgical | 5 |
| 27 | M | 62 | AF | L5/S1 | PM | 5 |
| 28 | M | 62 | NP | L5/S1 | PM | 5 |
| 29 | M | 74 | AF | L4/5 | PM | 5 |
| 30 | M | 74 | AF | L2/3 | PM | 6 |
| 31a | F | 49 | NP | L5/S1 | Surgical | 8 |
| 32 | F | 15 | Tissue | L4/5 | Surgical | 0 |
| 33 | F | 27 | Tissue | L5/S1 | Surgical | 0 |
| 34 | M | 39 | Tissue | L4/5 | Surgical | 0 |
| 35 | F | 44 | Tissue | L4/5 | Surgical | 0 |
| 36 | F | 20 | Tissue | L5/S1 | Surgical | 2 |
| 37 | M | 40 | Tissue | L4/5 | Surgical | 2 |
| 38 | M | 47 | Tissue | L4/5 | Surgical | 2 |
| 39 | F | 27 | Tissue | L4/5 | Surgical | 3 |
| 40 | M | 31 | Tissue | L4/5 | Surgical | 3 |
| 41 | F | 57 | Tissue | L4/5 | Surgical | 3 |
| 42 | M | 59 | Tissue | L5/S1 | Surgical | 3 |
| 43 | M | 28 | Tissue | L4/5 | Surgical | 5 |
| 44 | F | 34 | Tissue | L3/4 | Surgical | 5 |
| 45 | M | 39 | Tissue | L5/S1 | Surgical | 5 |
| 46 | M | 55 | Tissue | L3/4 | Surgical | 5 |
| 47 | F | 27 | Tissue | L4/5 | Surgical | 7 |
| 48 | F | 56 | Tissue | L5/S1 | Surgical | 7 |
| 49 | M | 33 | Tissue | L5/S1 | Surgical | 8 |
| 50 | F | 40 | Tissue | L4/5 | Surgical | 8 |
| 51 | M | 54 | Tissue | L4/5 | Surgical | 8 |
| 52 | M | 32 | Tissue | L4/5 | Surgical | 10 |
| 53 | F | 41 | Tissue | L5/S1 | Surgical | 12 |
Intervertebral disc samples 1 to 31 were used for telomere length assay, and samples 32 to 53 were used for p16immunohistochemistry. aIntervertebral disc samples used for senescence-associated β-galactosidase staining. AF, annulus fibrosus; F, female; M, male; NP, nucleus pulposus; PM, postmortem tissue.
Polymerase chain reaction primer and probe sequences, amplicon sizes, and efficiencies
| Standard polymerase chain reaction conditions | ||||
| Target | Forward primer | Reverse primer | Amplicon size | |
| GAPDH | 5' CCC ATC ACC ATC TTC CAG G 3' | 5' GGC CAT CCA CAG TCT TCT G 3' | 354 bp | |
| hTERT | 5' GCC TGA GCT GTA CTT TGT CAA 3' | 5' AGG CTG CAG AGC AGC GTG GAG AGG 3' | 422 bp | |
| Real-time polymerase chain reaction primers and probes | ||||
| Target | Forward primer | Probe | Reverse primer | Efficiency |
| 18s | PDAR | PDAR | PDAR | 99.65% |
| P16 | 5' GGC TCT ACA CAA GCT TCC TTT CC 3' | 5' 6 FAM – CCC CCA CCC TGG CTC TGA CCA – TAMRA | 5' TCA TGA CCT GCC AGA GAG AAC A 3' | 99.22% |
| MMP-13 | 5' CCC CAG GCA TCA CCA TTC AAG 3' | 5' 6 FAM – AGG GGT CCT GGC TGC CTT CCT CTT C – TAMRA 3' | 5' GAC AAA TCA TCT TCA TCA CCA CCA C 3' | 99.77% |
| ADAMTS 5 | 5' GGA CCT ACC ACG AAA GCA GAT C 3' | 5' 6 FAM – CCC AGG ACA GAC CTA CGA TGC CAC C – TAMRA 3' | 5' GCC GGG ACA CAC GGA GTA 3' | 99.74% |
ADAMTS 5, a disintegrin and metalloprotease with thrombospondin motifs 5; bp, base pairs; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hTERT, human telomerase reverse transcriptase; MMP-13, matrix metalloproteinase-13; PDAR, pre-developed assay reagent.
Figure 1The expression of senescence biomarkers in vivo. (a) Mean telomere length (MTL) in cells directly extracted from non-degenerate and degenerate human intervertebral discs (IVDs): correlation with age. Samples are from 20 non-degenerate discs (6 aged 37 years, 7 aged 47 years, 2 aged 59 years, 4 aged 62 years, and 1 aged 74 years), 10 intermediate degenerate discs (4 aged 37 years, 1 aged 44 years, 1 aged 49 years, 2 aged 62 years, and 2 aged 74 years), and 1 severely degenerate disc (aged 49 years). Spearman rank correlation P < 0.05. (b) MTL in cells directly extracted from non-degenerate and degenerate human IVDs: effect of degree of degeneration. *Intermediate degenerate samples are significantly different from non-degenerate samples (P < 0.05). Disc samples are as described in (a). Data are shown as average MTL ± standard error of the mean (SEM) for each disease state. (c) Quantification and localisation of p16immunopositivity in human IVDs correlated with degree of degeneration. *Samples are significantly different from non-degenerate samples (P < 0.05). Samples are from 11 non-degenerate discs, 6 intermediate degenerate discs, and 5 severely degenerate discs. Averages ± SEM are presented. (d) p16immunopositive cells in human IVDs correlated with age. Samples are as detailed in (c). Intermediate degenerate (grades 4 to 7) and severely degenerate (grades 8 to 12) samples are grouped for correlation analysis. Spearman rank correlation for non-degenerate samples P < 0.05 and for degenerate samples P = 0.26. IAF, inner annulus fibrosus; kbp, kilobase pairs; NP, nucleus pulposus; OAF, outer annulus fibrosus.
Figure 2Senescence biomarker immunohistochemistry. (a) p16immunopositivity in the nucleus pulposus of human intervertebral discs. (b) Immunoglobulin G controls were negative. (c) Senescence-associated β-galactosidase staining in directly extracted cells from non-degenerate discs. (d) Senescence-associated β-galactosidase staining in directly extracted cells from degenerate discs (positive cells indicated with arrows). Scale bars = 190 μm (a, b) and 370 μm (c, d).
Figure 3Senescence biomarkers in human intervertebral disc (IVD) cells in vitro. (a) Cell growth kinetics: cumulative population doublings in nucleus pulposus (NP) cells extracted from non-degenerate and degenerate IVDs. (b) Percentage of life span completed over time in culture of NP cells extracted from non-degenerate and degenerate IVDs. (c) Mean telomere length in NP cells extracted from non-degenerate and degenerate IVDs with increasing population doubling. Samples used consisted of two non-degenerate discs from one post mortem (L2/3: grade 1, L4/5: grade 2; 37-year-old male) and two degenerate discs from one patient undergoing surgery (L4/5: grade 4, L5/S1: grade 8; 49-year-old male).
Figure 4Correlation of senescent phenotype with expression of matrix-degrading enzymes. (a) Correlation of MMP-13 and p16gene expression in human intervertebral disc (IVD) cells. Spearman rank correlation P < 0.05. (b) Correlation of ADAMTS 5 and p16gene expression in human IVD cells. Spearman rank correlation P < 0.05. ADAMTS 5, a disintegrin and metalloprotease with thrombospondin motifs 5; MMP-13, matrix metalloproteinase-13.